On November 2, 2026, the independent members of the Board of Directors of Guardant Health, Inc. approved the grant of performance-based restricted stock units to each of the Company's founders and Co-Chief Executive Officers, Helmy Eltoukhy and AmirAli Talasaz. Each Co-CEO receiv

Guardant Health, Inc. Grants 465,413 Target Performance-Based Restricted Stock Units to Each Co-CEO

Fintel reports that on October 23, 2026, Roth Capital initiated coverage of Guardant Health (NASDAQGS:GH) (BIT:1GH) with a Buy recommendation. Guardant Health, Inc., based in the United States, operates primarily in the biotechnology industry with a specialized focus on oncology.

Roth Capital Initiates Coverage of Guardant Health at Buy

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2500 ETF (Symbol: SMMD) where we have detected an approximate $285.2 million dollar inflow -- that's a 7.5% increase week over week i

SMMD, GH, SOFI, SNX: Large Inflows Detected at ETF

Insider reported a trade at Guardant Health, Inc.

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care. The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients. The Guardant360 CDx breast...

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health, Inc. News